Physician profile
Diely A Pichardo
NPI 1194701573
$2,358.82
in general payments reported to CMS, 2019-2025
43 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,830 · 2020: $513 · 2022: $16.08.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $211.22 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $207.48 | 2019-2020 | |
| Astellas Pharma US INC | $184.58 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $163.12 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $151.03 | 2019-2020 | |
| Lilly USA, LLC | $118.53 | 2019 | |
| Janssen Biotech, INC. | $105.15 | 2019-2020 | |
| Pfizer INC. | $87.04 | 2019-2020 | |
| Genzyme Corporation | $72.26 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $70.35 | 2019-2020 | |
| Celgene Corporation | $67.81 | 2019 | |
| Clovis Oncology, INC. | $57.80 | 2019-2020 | |
| Eisai INC. | $56.48 | 2019-2020 | |
| Amgen INC. | $50.75 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $48.69 | 2019-2020 |
Show all 43 companies
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diely Pichardo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.